EMERYVILLE, Calif., April 16, 2021 (GLOBE NEWSWIRE) --  Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced new findings from an investigator-initiated study designed to assess caregivers’ perspectives on the long-term seizure- and non-seizure-related benefits of FINTEPLA® (fenfluramine) on patients with Dravet syndrome, a rare, severe epilepsy, and on their caregivers and families. Data from the study is being presented during the virtual American Academy of Neurology (AAN) Annual Meeting, April 17-22, 2021.

See original here:
Zogenix Presents New Data from a Study Highlighting the Impact of Treatment with FINTEPLA® (Fenfluramine) Oral Solution on Dravet Syndrome Patients,...